SATIVEX Trademark

Trademark Overview


On Wednesday, November 16, 2022, a trademark application was filed for SATIVEX with the United States Patent and Trademark Office. The USPTO has given the SATIVEX trademark a serial number of 79357367. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, November 20, 2024. This trademark is owned by GW Pharma Limited. The SATIVEX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary preparations for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for use in treating pain,...

General Information


Serial Number79357367
Word MarkSATIVEX
Filing DateWednesday, November 16, 2022
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, November 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and veterinary preparations for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pure extracts of medicinal plants and herbs; foodstuffs for medicinal purposes, namely, dietetic foods adapted for medical use; herb teas for medicinal purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 12, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGW Research Limited
Party Type11 - New Owner Before Publication
Legal Entity Type98 - Unknown
AddressGB

Party NameGW Pharma Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGB

Trademark Events


Event DateEvent Description
Thursday, December 8, 2022SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Monday, December 12, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 16, 2022APPLICATION FILING RECEIPT MAILED
Thursday, January 5, 2023INTERNATIONAL REGISTRATION RENEWED
Wednesday, August 30, 2023ASSIGNED TO EXAMINER
Thursday, September 7, 2023NON-FINAL ACTION WRITTEN
Friday, September 8, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, September 26, 2023REFUSAL PROCESSED BY MPU
Tuesday, September 26, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, October 16, 2023REFUSAL PROCESSED BY IB
Tuesday, March 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 26, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 26, 2024NON-FINAL ACTION WRITTEN
Friday, April 26, 2024NON-FINAL ACTION E-MAILED
Friday, April 26, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 8, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, May 8, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Friday, May 31, 2024CHANGE OF OWNER RECEIVED FROM IB
Sunday, June 2, 2024REFUSAL PROCESSED BY IB
Tuesday, June 11, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, November 20, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, November 20, 2024ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND